Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 83.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 0 · 0%High 0 · 0%

Heparin vs low molecular weight heparin

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heparin vs prostaglandin E1

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heparin vs no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia

Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.66 [0.25, 1.76]
1 study · 161 participants
Low

Low molecular weight heparin vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs prostaglandin E1

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found